One of the first inhibitors of the VISTA/VSIG-3 interaction was the compound CA-170 (Figure 7), which is currently in Phase II clinical trials for lung, head, and neck/oral cancers, as well as Hodgkin lymphoma and MSI-H positive cancers [277]. This evidence concerns the gene IGSF11 and cancer.